Safe Superintelligence Inc (SSI) was co-founded in June 2023 by Ilya Sutskever, former chief scientist at OpenAI, alongside Daniel Gross (former Apple AI lead and Y Combinator partner) and Daniel Levy (former OpenAI researcher). The departure of Sutskever — one of the most respected figures in AI research — following the turbulent OpenAI board episode made SSI one of the most-watched startups in AI history.
Mission and Approach
SSI’s stated mission is the singular focus on building safe superintelligence. The company explicitly rejects the typical startup path of shipping commercial products to fund research, arguing that commercial pressures are fundamentally incompatible with the safety-first approach required to build superintelligence responsibly. This unusual structure allows researchers to work on long-horizon problems without product deadlines.
Funding and Structure
SSI raised $1 billion in its initial funding round at a reported valuation above $5 billion — extraordinary for a company with no product and no near-term commercial revenue. The funding came from top-tier investors willing to bet on the team’s pedigree rather than a business model. The company has offices in Palo Alto and Tel Aviv, reflecting Sutskever’s connections to the Israeli research community.
Competitive Position
SSI occupies a unique position as a pure research lab competing with Anthropic and DeepMind for safety-focused talent. By explicitly disavowing commercial pressure, SSI can attract researchers who want to work on foundational alignment problems without the tension between safety and capability deployment that characterizes more commercial labs. The key risk is whether the no-product model is sustainable long-term and whether research outputs will be published or kept proprietary.
Outlook
SSI’s long-term significance depends on whether safety-first approaches to superintelligence produce results that matter. The company has deliberately said very little about its technical direction, which makes it difficult to assess progress. Sutskever’s scientific credibility is SSI’s primary asset, and the company will likely be judged over a 5-10 year horizon rather than near-term product milestones.